A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.
Astellas Pharma has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan among its clients.
Vertex Pharmaceuticals has turned to Genomics to support its attempts to understand the genetic basis of drug targets and diseases. The deal gives Vertex access to an integrated database and analysis tools developed by Genomics, resources it sees advancing its work to validate disease mechanisms.
Sanofi has enlisted Global Genomics Group (G3) to help its hunt for the next generation of targets for cardiovascular diseases. The deal gives Sanofi access to data from a 7,500-person study run by G3, plus bioinformatics capabilities the genomics player has built to sift through the results.
Cancer Research UK has unveiled version 3.0 of its oncology drug discovery database. The latest iteration of the platform contains more than 110,000 3-D structures for nearly 22,000 proteins, a resource the team behind the database thinks will support improved target selection.
Astellas has turned to Biovista for help finding new indications for some of its existing compounds. The project is underpinned by Biovista's Clinical Outcome Search Space technology, a tool that combines literature searches and in silico modeling to spot links between drugs and targets.
Amazon has made The Cancer Genome Atlas and The International Cancer Genome Consortium PanCancer data sets freely available through its cloud platform. The addition of the data sets continues Amazon's push to differentiate its cloud offering through the availability of data.
Genomics England has picked Cognizant to help design and set up the IT backbone of its massive sequencing project. The two-year agreement gives Cognizant a starring role in the creation of the IT operating environment used by the 100,000 Genomes Project.
The former CEO of Chinese sequencing giant BGI has started his new venture, iCarbonX. As expected, iCarbonX will build a deep, broad pool of health data and develop an artificial intelligence platform to dig into the resource for insights into how to treat diseases.
Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.